scholarly journals PCN106 - ECONOMIC BURDEN OF END-OF-LIFE AGGRESSION IN LUNG CANCER PATIENTS FROM THE FRENCH HEALTH INSURER PERSPECTIVE

2018 ◽  
Vol 21 ◽  
pp. S32
Author(s):  
O. Bylicki ◽  
C. Blein ◽  
C. Tournier ◽  
F. Canoui-Poitrine ◽  
C. Chouaid
Keyword(s):  
Lung Cancer ◽  
End Of Life ◽  
Cancer Patients ◽  
Economic Burden ◽  
Health Insurer ◽  
Lung Cancer Patients

Outcomes of Embedded Palliative Care Outpatients Initial Consults on Timing of Palliative Care Access, Symptoms, and End-of-Life Quality Care Indicators among Advanced Nonsmall Cell Lung Cancer Patients

2018 ◽  
Vol 21 (12) ◽  
pp. 1690-1697 ◽  
Author(s):  
Sriram Yennurajalingam ◽  
Bernard Prado ◽  
Zhanni Lu ◽  
Syed Naqvi ◽  
Janet L. Williams ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Palliative Care ◽  
End Of Life ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Quality Care ◽  
Life Quality ◽  
Nonsmall Cell Lung Cancer ◽  
Lung Cancer Patients ◽  
Care Access

OP456 Encouraging Shared Decision-Making Of Goals Of Care Discussions In Lung Cancer Patients Using A Smartphone Application

2021 ◽  
Vol 37 (S1) ◽  
pp. 17-17
Author(s):  
Amanda Lovato ◽  
Nisha Almeida
Keyword(s):  
Lung Cancer ◽  
Palliative Care ◽  
Focus Groups ◽  
End Of Life ◽  
Cancer Patients ◽  
Smartphone Application ◽  
Quality Improvement Initiative ◽  
Care Hospital ◽  
Goals Of Care ◽  
Lung Cancer Patients

IntroductionAn important reason for receiving non-beneficial treatment at end-of life is the lack of timely discussions on goals of care and end-of-life preferences. A recent randomized clinical trial demonstrated that patients primed with a questionnaire on their end-of-life preferences were more likely to initiate such conversations with their doctors. Our objective is to integrate the questionnaire into a smartphone application to facilitate early goals of care discussions. To achieve this goal, we first plan to undertake a feasibility study to understand stakeholder preferences.MethodsAs part of a quality improvement initiative at our Canadian quaternary-care hospital, we conducted focus groups with oncology and palliative care physicians and patients to understand barriers to early conversations on end-of-life preferences, and to assess feasibility of using smartphone technology in facilitating these conversations. The app would integrate a questionnaire to patients and send prompts to physicians on patient readiness and timing of conversations.ResultsWe conducted separate focus groups with lung cancer patients (n = 6) and clinicians in oncology (n = 6) and palliative care (n = 6). Clinical teams expressed enthusiasm about early conversations but raised several barriers including system (lack of electronic documentation and access to data; multiple physicians), clinician (lack of time) and patient (stigma associated with end-of-life) barriers. Clinicians agreed that an app could overcome some of these barriers such as access to patient and electronic data by making patients the repository of all their data and empowering them to initiate discussions. However, they raised concerns about universal accessibility of such technology, especially among the elderly. Patient focus groups will take place in March 2021 and inform us on feasibility in this population.ConclusionsThere is a consensus among physicians at our hospital that early end-of-life conversations have the potential to mitigate adverse events and that use of a smart phone app could facilitate such conversations.

Factors Affecting Racial Disparities in End-of-Life Care Costs Among Lung Cancer Patients

2019 ◽  
Vol 42 (2) ◽  
pp. 143-153 ◽  
Author(s):  
Siddharth Karanth ◽  
Suja S. Rajan ◽  
Frances L. Revere ◽  
Gulshan Sharma
Keyword(s):  
Lung Cancer ◽  
Racial Disparities ◽  
End Of Life ◽  
Cancer Patients ◽  
End Of Life Care ◽  
Life Care ◽  
Factors Affecting ◽  
Lung Cancer Patients ◽  
Care Costs

scholarly journals P1.16-12 An Analysis of Healthcare Use and the Cost Associated to End-of-Life Care of Lung Cancer Patients in a Spanish Hospital

2019 ◽  
Vol 14 (10) ◽  
pp. S590-S591
Author(s):  
J.L. Cruz ◽  
M. Provencio ◽  
E. Menasalvas ◽  
C. Parejo ◽  
F. Martínez-Ruíz ◽  
...  
Keyword(s):  
Lung Cancer ◽  
End Of Life ◽  
Cancer Patients ◽  
End Of Life Care ◽  
Life Care ◽  
Healthcare Use ◽  
Lung Cancer Patients ◽  
Spanish Hospital ◽  
The Cost

End of life treatment of metastatic lung cancer patients in the Netherlands

2017 ◽  
Author(s):  
Gea Douma ◽  
Heidi P. Fransen ◽  
Ben J.W. Venmans ◽  
Mieke J. Aarts
Keyword(s):  
Lung Cancer ◽  
The Netherlands ◽  
End Of Life ◽  
Cancer Patients ◽  
Metastatic Lung Cancer ◽  
Lung Cancer Patients ◽  
Metastatic Lung ◽  
End Of Life Treatment

Anti-dementia and anti-hyperlipidemic medication use at end of life in elderly lung cancer patients: Analysis of SEER-Medicare data.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 10027-10027 ◽  
Author(s):  
Min Ji Kim ◽  
Zhigang Duan ◽  
Hui Zhao ◽  
Holly Michelle Holmes ◽  
Joanna-Grace Mayo Manzano ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Drug Use ◽  
End Of Life ◽  
Cancer Patients ◽  
Cholesterol Absorption ◽  
Study Endpoint ◽  
Lung Cancer Patients ◽  
Bile Acid Sequestrants ◽  
Before And After ◽  
Hospice Use

10027 Background: Despite risk for polypharmacy, elderly cancer patients may receive drugs whose time to benefit likely exceeds life expectancy. This study aims to describe use of drugs considered potentially unnecessary, namely anti-hyperlipidemics and anti-dementia drugs, and to identify factors associated with their use in Stage 3 or 4 non-small cell lung cancer (NSCLC) patients approaching end of life. Methods: We identified all patients older than 65 diagnosed with primary Stage 3 or 4 NSCLC between 2006 and 2011 in the Surveillance, Epidemiology and End Results (SEER)-Medicare database. Information on drug prescriptions was extracted from Medicare Part D files. First-time hospice enrollment or death date was used as the final endpoint in analysis. The primary outcome was use of drugs of interest at 4 months before NSCLC diagnosis, 6 months and 3 months before death or hospice. Associations with demographic or other factors were tested using the Pearson χ2 test. Results: Of all 7983 patients, 45.1% were taking statins before diagnosis, while 40.7% and 30.9% were still taking statins at 6 and 3 months before death or hospice. Use of bile acid sequestrants, fibric acid derivatives, and cholesterol absorption inhibitors were found to decrease toward death or hospice. In contrast, anti-dementia drug use did not decrease, with 3.4% before diagnosis and 4.2% and 3.5% at 6 and 3 months before death or hospice. Approximately 30% of anti-dementia medications were newly prescribed at 6 and 3 months before study endpoint. Having a higher number of prescriptions at 3 months before death or hospice was associated with higher rates of drug use both before and after cancer diagnosis. Having a higher Charlson comorbidity index correlated with greater anti-dementia drug use before diagnosis. Demographic, socioeconomic, and treatment factors were not found to be correlated with drug use. Conclusions: A high prevalence of statin use persists while a notable proportion of anti-dementia drugs are newly prescribed toward death or hospice. Our findings suggest an opportunity for clinicians to re-evaluate risks and benefits of potentially unnecessary medications in elderly patients nearing end of life.

scholarly journals Racial-Ethnic Disparities in End-of-Life Care Quality among Lung Cancer Patients: A SEER-Medicare–Based Study

2018 ◽  
Vol 13 (8) ◽  
pp. 1083-1093 ◽  
Author(s):  
Siddharth Karanth ◽  
Suja S. Rajan ◽  
Gulshan Sharma ◽  
Jose-Miguel Yamal ◽  
Robert O. Morgan
Keyword(s):  
Lung Cancer ◽  
End Of Life ◽  
Cancer Patients ◽  
End Of Life Care ◽  
Ethnic Disparities ◽  
Care Quality ◽  
Life Care ◽  
Lung Cancer Patients ◽  
Racial Ethnic

End-of-life cost for lung cancer patients in Greece: a hospital-based retrospective study

2021 ◽  
Vol 10 (4) ◽  
pp. 315-324
Author(s):  
Eleni Kokkotou ◽  
Garyfallia Stefanou ◽  
Nikolaos Syrigos ◽  
George Gourzoulidis ◽  
Eleutheria Ntalakou ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Retrospective Study ◽  
Small Cell Lung Cancer ◽  
End Of Life ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Patients ◽  
The Mean

Objective: The aim of the present study was to estimate the cost of treating patients with lung cancer at their end-of-life (EOL) phase of care in Greece. Materials & methods: A hospital-based retrospective study was conducted in the Oncology Unit of ‘Sotiria’ Hospital, in Athens, Greece. All lung cancer patients who died between 1 January 2015 and 31 December 2018 with at least 6 months follow-up were enrolled in the study. Healthcare resource utilization data, including inpatient and outpatient ones, during the last 6 months before death was extracted from a registry kept in the unit. This data were combined with the corresponding local unit costs to calculate the 6, 3 and 1-month EOL cost in €2019 values. Results: A total of 122 patients met the inclusion criteria. The mean (standard deviation) age at diagnosis was 67.8 (8.9) years with 78.7% of patients being male and 55.0% diagnosed at stage IV. About 52.5% of patients had been diagnosed with adenocarcinoma, 28.7% with squamous non-small-cell lung cancer types and 18.9% with small-cell-lung cancer. The median overall survival of these patients was 10.8 months. During the EOL periods, the mean cost/patient in the last 6, 3 and 1 month were €7665, €3351 and €1009, respectively. Pharmaceutical cost was the key driver of the total cost (75% of the total 6-month) followed by radiation therapy (16.2%). The median EOL 6-month cost was marginally statistically significantly higher among patients with adenocarcinoma (€9031) compared with squamous (€6606) and to small-cell-lung cancer (€5474). Conclusion: The findings of the present study indicate that lung cancer treatment incurs high costs in Greece, mainly attributed to pharmaceutical expenses, even at the EOL phase.

Rural versus urban differences in end-of-life care for lung cancer patients in Germany

2018 ◽  
Vol 26 (7) ◽  
pp. 2275-2283 ◽  
Author(s):  
Julia Walter ◽  
Amanda Tufman ◽  
Reiner Leidl ◽  
Rolf Holle ◽  
Larissa Schwarzkopf
Keyword(s):  
Lung Cancer ◽  
End Of Life ◽  
Cancer Patients ◽  
End Of Life Care ◽  
Life Care ◽  
Lung Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document